About

 

Urticaria, commonly known as hives or wheals, is an acute or chronic inflammatory skin condition characterized by the sudden onset of raised, erythematous lesions with well-demarcated borders that are typically intensely pruritic. Individual lesions are transient, often lasting minutes to hours before resolving spontaneously without leaving residual marks, though new lesions may continue to appear. Urticaria results from mast cell degranulation leading to release of inflammatory mediators such as histamine, which causes vasodilation, increased vascular permeability, and localized edema in the dermis. The condition can occur as isolated episodes or persist as a chronic disorder, significantly impacting quality of life, sleep, and psychological well-being due to the unpredictable nature of flares and persistent itching.

​

Urticaria is one of the most common skin conditions worldwide, affecting approximately 15-20% of the population at some point during their lifetime, with approximately 1-3% experiencing chronic urticaria lasting more than six weeks. Urticaria can occur at any age but is most common in young adults and shows a slight female predominance. The condition often occurs in conjunction with angioedema, a deeper tissue swelling affecting the dermis and subcutaneous tissues, typically involving the face and lips. While acute urticaria is usually self-limiting and benign, chronic urticaria can profoundly affect patient quality of life, causing sleep disturbance, reduced work productivity, and psychological distress. Additionally, urticaria can rarely involve systemic symptoms or progress to life-threatening anaphylaxis, particularly when associated with angioedema affecting the airway, necessitating prompt recognition and treatment.

​

Causes

 

Urticaria results from mast cell and basophil degranulation triggering release of inflammatory mediators, but the underlying causes are diverse and often remain unidentified. IgE-mediated allergic reactions represent a common etiology, with triggers including food allergens (peanuts, tree nuts, shellfish, eggs, milk), medications (particularly penicillins and NSAIDs), insect venom, and environmental allergens. Non-allergic triggers account for a substantial proportion of urticaria cases, including physical urticarias induced by specific stimuli such as cold, heat, sunlight, pressure, vibration, or exercise. Infections, particularly viral infections including upper respiratory tract infections, hepatitis, and other systemic infections, frequently trigger acute urticaria and may be responsible for the initial onset of chronic urticaria.

​

Chronic urticaria, persisting beyond six weeks, often has no identifiable specific trigger and is frequently associated with autoimmune mechanisms where patient sera contain IgE or IgG autoantibodies against high-affinity IgE receptors on mast cells or IgE itself. Psychological stress and emotional factors can precipitate or exacerbate urticaria through neuroimmune pathways and catecholamine release. Medications including antihistamines used paradoxically, ACE inhibitors, NSAIDs, and aspirin can trigger or worsen urticaria in susceptible individuals. Systemic diseases including thyroid autoimmunity, systemic lupus erythematosus, and other connective tissue disorders are associated with chronic urticaria. Additionally, food additives, food preservatives, artificial colorants, and other chemical irritants may trigger urticaria in sensitive individuals. Environmental factors such as temperature changes, humidity, perspiration, and friction can exacerbate existing urticaria, while parasitic infections and malignancy, though less common, should be considered in cases of persistent unexplained urticaria.

​

Solutions

 

Treatment of urticaria begins with identification and avoidance of identified triggers whenever possible, combined with pharmacological management to control symptoms. First-line therapy involves non-sedating second-generation antihistamines such as cetirizine, loratadine, desloratadine, and fexofenadine, which block histamine H1-receptors and effectively suppress pruritus and lesion formation in most acute urticaria cases. For acute urticaria, short courses of systemic corticosteroids may be warranted to rapidly suppress inflammation, though prolonged use should be avoided due to side effect risks. In cases of acute urticaria with systemic symptoms or angioedema, intramuscular epinephrine may be necessary, particularly if anaphylaxis is suspected. Patients should be provided with antihistamine education regarding appropriate dosing, timing, and realistic expectations for symptom control.

​

Chronic urticaria management requires a more aggressive and sustained approach due to the persistent nature of the condition. Second-generation antihistamines remain the cornerstone of therapy, and dosages may be escalated up to four-fold the standard doses in patients with inadequate response. If antihistamine monotherapy proves insufficient, omalizumab (an anti-IgE monoclonal antibody) has demonstrated significant efficacy in reducing urticaria activity and is approved for chronic urticaria refractory to antihistamines. Cyclosporine is reserved for severe cases resistant to other therapies but requires careful monitoring due to immunosuppressive effects. Identification of underlying causes such as occult infections, thyroid disease, or systemic conditions is important for chronic urticaria, with appropriate treatment of identified etiologies. Comprehensive management should include education regarding trigger avoidance, stress reduction techniques, and maintenance of skin integrity. Patients should maintain an urticaria diary to identify patterns and potential triggers, and receive epinephrine auto-injectors if there is risk of anaphylaxis. Regular reassessment and medication adjustment based on disease control, along with psychological support when needed, optimizes outcomes and improves quality of life for individuals with acute and chronic urticaria.